1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/56515
Full metadata record
DC FieldValueLanguage
dc.creatorPedro Ricardokömel Pimentapt_BR
dc.creatorMichael Ruberson Ribeiro da Silvapt_BR
dc.creatorJéssica Barreto Ribeiro Dos Santospt_BR
dc.creatorAdriana Maria Kakehasipt_BR
dc.creatorFrancisco de Assis Acurciopt_BR
dc.creatorJuliana Alvares Teodoropt_BR
dc.date.accessioned2023-07-17T20:39:21Z-
dc.date.available2023-07-17T20:39:21Z-
dc.date.issued2021-
dc.citation.volume10pt_BR
dc.citation.issue6pt_BR
dc.citation.spage509pt_BR
dc.citation.epage517pt_BR
dc.identifier.doihttps://becarispublishing.com/doi/10.2217/cer-2020-0275pt_BR
dc.identifier.issn2042-6305pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/56515-
dc.description.resumoAim: To evaluate the effectiveness and safety of anti-TNF drugs for ankylosing spondylitis. Materials & methods: A prospective cohort study was performed at a pharmacy in the Brazilian Public Health System. Effectiveness by Bath Ankylosing Spondylitis Disease Activity Index, functionality by Health Assessment Questionnaire Disability Index, quality of life by European Quality of Life Five-Dimensions and safety was assessed at 6 and 12 months of follow-up. Results: About 160 patients started the treatment with adalimumab, etanercept or infliximab. There was a statistically significant improvement in disease activity, functionality and quality of life at 6 and 12 months (p < 0.05). Conclusion: This real-world study has shown that anti-TNF drugs are effective and well tolerated for ankylosing spondylitis patients.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIALpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE APARELHO LOCOMOTORpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofJournal of Comparative Effectiveness Researchpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectAnkylosing spondylitispt_BR
dc.subjectEffectivenesspt_BR
dc.subjectObservational studypt_BR
dc.subjectSafetypt_BR
dc.subjectTumor necrosis factor inhibitorspt_BR
dc.subject.otherEspondilite anquilosantept_BR
dc.subject.otherEficaciapt_BR
dc.subject.otherInibidorespt_BR
dc.titleEffectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world studypt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://doi.org/10.2217/cer-2020-0275pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-4024-0108pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-2550-7249pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-5528-0658pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-9411-7493pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-5880-5261pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0210-0721pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis a real-world study.pdf223.51 kBAdobe PDFView/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.